These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
833 related articles for article (PubMed ID: 19523946)
1. Staphylococcal enterotoxin B is involved in aggravation and recurrence of murine experimental autoimmune uveoretinitis via Vbeta8+CD4+ T cells. Kohno H; Sakai T; Tsuneoka H; Imanishi K; Saito S Exp Eye Res; 2009 Oct; 89(4):486-93. PubMed ID: 19523946 [TBL] [Abstract][Full Text] [Related]
2. Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype. Avichezer D; Silver PB; Chan CC; Wiggert B; Caspi RR Invest Ophthalmol Vis Sci; 2000 Jan; 41(1):127-31. PubMed ID: 10634611 [TBL] [Abstract][Full Text] [Related]
3. Evidence for selective accumulation of V beta 8+ T lymphocytes in experimental autoimmune uveoretinitis induced with two different retinal antigens. Egwuagu CE; Mahdi RM; Nussenblatt RB; Gery I; Caspi RR J Immunol; 1993 Aug; 151(3):1627-36. PubMed ID: 8393049 [TBL] [Abstract][Full Text] [Related]
4. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity. Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291 [TBL] [Abstract][Full Text] [Related]
5. Mapping immune responses to mRBP-3 1-16 peptide with altered peptide ligands. Guyver CJ; Copland DA; Calder CJ; Sette A; Sidney J; Dick AD; Nicholson LB Invest Ophthalmol Vis Sci; 2006 May; 47(5):2027-35. PubMed ID: 16639012 [TBL] [Abstract][Full Text] [Related]
6. CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response. Takeuchi A; Usui Y; Takeuchi M; Hattori T; Kezuka T; Suzuki J; Okunuki Y; Iwasaki T; Haino M; Matsushima K; Usui M Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3753-60. PubMed ID: 16186359 [TBL] [Abstract][Full Text] [Related]
7. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. Caspi RR; Roberge FG; Chan CC; Wiggert B; Chader GJ; Rozenszajn LA; Lando Z; Nussenblatt RB J Immunol; 1988 Mar; 140(5):1490-5. PubMed ID: 3346541 [TBL] [Abstract][Full Text] [Related]
8. Contribution of CD4+CD25+ T cells to the regression phase of experimental autoimmune uveoretinitis. Sun M; Yang P; Du L; Zhou H; Ren X; Kijlstra A Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):383-9. PubMed ID: 19696173 [TBL] [Abstract][Full Text] [Related]
9. Establishment and characterization of a murine CD4+ T cell line and clone that induce experimental autoimmune uveoretinitis in B10.A mice. Rizzo LV; Silver P; Wiggert B; Hakim F; Gazzinelli RT; Chan CC; Caspi RR J Immunol; 1996 Feb; 156(4):1654-60. PubMed ID: 8568272 [TBL] [Abstract][Full Text] [Related]
10. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Hohki S; Ohguro N; Haruta H; Nakai K; Terabe F; Serada S; Fujimoto M; Nomura S; Kawahata H; Kishimoto T; Naka T Exp Eye Res; 2010 Aug; 91(2):162-70. PubMed ID: 20420831 [TBL] [Abstract][Full Text] [Related]
11. Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan. Okunuki Y; Usui Y; Nagai N; Kezuka T; Ishida S; Takeuchi M; Goto H Invest Ophthalmol Vis Sci; 2009 May; 50(5):2255-61. PubMed ID: 19136706 [TBL] [Abstract][Full Text] [Related]
12. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Sartani G; Silver PB; Rizzo LV; Chan CC; Wiggert B; Mastorakos G; Caspi RR Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2211-8. PubMed ID: 8843907 [TBL] [Abstract][Full Text] [Related]
13. IL-18 not required for IRBP peptide-induced EAU: studies in gene-deficient mice. Jiang HR; Wei X; Niedbala W; Lumsden L; Liew FY; Forrester JV Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):177-82. PubMed ID: 11133864 [TBL] [Abstract][Full Text] [Related]
14. Orally induced bystander suppression in experimental autoimmune uveoretinitis occurs only in the periphery and not in the eye. Wildner G; Thurau SR Eur J Immunol; 1995 May; 25(5):1292-7. PubMed ID: 7774632 [TBL] [Abstract][Full Text] [Related]
15. Prevention of experimental autoimmune uveoretinitis by monoclonal antibody to interleukin-12. Yokoi H; Kato K; Kezuka T; Sakai J; Usui M; Yagita H; Okumura K Eur J Immunol; 1997 Mar; 27(3):641-6. PubMed ID: 9079803 [TBL] [Abstract][Full Text] [Related]
16. Uveitogenicity is associated with a Th1-like lymphokine profile: cytokine-dependent modulation of early and committed effector T cells in experimental autoimmune uveitis. Xu H; Rizzo LV; Silver PB; Caspi RR Cell Immunol; 1997 May; 178(1):69-78. PubMed ID: 9184700 [TBL] [Abstract][Full Text] [Related]
17. Adoptive transfer of experimental autoimmune uveoretinitis induced by interphotoreceptor retinoid-binding protein. Kawashima H; FujiƱo Y; Mochizuki M Jpn J Ophthalmol; 1991; 35(1):51-60. PubMed ID: 1895569 [TBL] [Abstract][Full Text] [Related]
18. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. Jones LS; Rizzo LV; Agarwal RK; Tarrant TK; Chan CC; Wiggert B; Caspi RR J Immunol; 1997 Jun; 158(12):5997-6005. PubMed ID: 9190954 [TBL] [Abstract][Full Text] [Related]
19. Residues 1-20 of IRBP and whole IRBP elicit different uveitogenic and immunological responses in interferon gamma deficient mice. Avichezer D; Chan CC; Silver PB; Wiggert B; Caspi RR Exp Eye Res; 2000 Aug; 71(2):111-8. PubMed ID: 10930316 [TBL] [Abstract][Full Text] [Related]
20. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis. Tarrant TK; Silver PB; Chan CC; Wiggert B; Caspi RR J Immunol; 1998 Jul; 161(1):122-7. PubMed ID: 9647215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]